SLAMF7 and Miyoshi myopathy: Elotuzumab has multiple mechanisms of action against MM cells, including direct NK cell activation, antibody-dependent cytotoxicity via NK cells, antibody-dependent cell phagocytosis via macrophages, and neutralization of soluble SLAMF7 [1-4].